



Innovative Medicines Initiative

European Medicines Research Training Network















What patients need What Europe needs






The Education and Training projects will enhance Europe's biomedical education landscape to promote:

Innovation

Europe's global leadership in medicines research

Development of new, safer more effective medicines







What we will do about it

EMTRAIN will establish a sustainable, pan-European platform for education and training covering the whole lifecycle of medicines research, from basic science through clinical development to pharmacovigilance



European Union Member States







How will we do it?



By integrating the strengths and competencies of the:

- European Biological & Medical Sciences (BMS) Infrastructures
- EFPIA companies
- IMI E&T Projects (members of the Strategic Coordination Board)
- IMI Scientific Topics (members of the Network Committee) and
- External stakeholders (members of the External Advisory Board).



Innovative approach




- Unique, public private partnership
- Pan-European platform
- Building on previous
 success
- Empowering people
 - Course catalogue
 - Quality evaluated
 - Build individual competency portfolios
- Continuous review





Cross E&T Collaboration

- Course catalogue
- Tools & processes (e.g. Accreditation)
- Knowledge sharing
- Guidelines
- Communications (e.g. Students' Office)





Expected outcome





Pan-European platform

- Easier access to quality courses
- Links to national governments, universities,
- professional bodies & industry



State-of-the-art course catalogue

- Tailored to individual needs
- Incorporating IMI quality criteria
- Continuous feedback from users & improvements



New breed of "drug developers"

- Awareness of translational science
- Greater collaboration open innovation
- Life-long learning

Expected benefit to patients






Added value of the consortium



- Biobanking and Biomolecul Resources Research Infra (BBMRI)
- European Advanced T , O , onal Research Infrastruct , dedicine (EATRIS)
- European Clinic arch Infrastructures k (ECRIN)
- Upgrade of Infrastruct
- Europer structure for pheno' and archiving of model mar genomes (IN' ONTIER)
 - ed Structural Biology ructure (ELIXIR)

•

• 16 EFPIA companies (10 of the top 20 companies in the world)





Achievements so far



- Established open-source project management system
- Pan-European expansion
 - Hungary & Poland included
- Defined specification for course catalogue and chosen vendor
- Linked to Orpheus, Marie-Curie, EATRIS and industry for PhD programme
- Communication platform established
 - Web-site, E&T slide set, pamphlets, virtual student office
 - Cross-IMI E&T task force established
 - Orpheus, Stockholm Clinical Trials meeting, IMI Stakeholder meeting, WorldPharma 2010
- Interactions with Bologna experts, National Ministries Health & Education and Professional Bodies



On-line Project Management Tool




AT CORD	Post result	nes Research an			•			o	•					□ • + • ○		
	0	h.	0	in Colorador	3	2	.1	-X				•	•••••••••••••••••••••••••••••••••••••••		25	0
				the second second		Constant of			•					•		- and a second
201		124	1.1				-00		100	102	24	- 22		200	100	
Help: Sale	ct a Work	Parkane	- 2	EMTRAIN	-Over	all / Do	cume	nts	125		23	80			135	
undermealth				Search		-	4000									
		-22 .		Searce	12	-	15		191	16	23	1.0		213	1	
ENTRAN-	Overall				er ** Nes	w File	New o	ole 🍈 He	ye O Delete	& Config	12			200	1.00	
- Select you	v Work Peckag	ii÷S		and the second	1992		81.046	100000	States and	Secondary.	100	- 20			58	
WP 1 Mana	Distant.	1		Root/					•52	10.	0.8			•27	•02	
NP 3 Stress	age .	127	100						• concer =							
WF 5 Mapp WP 4 Apple		li na		+ D Appro	AN FPP	bles	1.5		. Title		. Description		Date.	Author		10 = .
NP 8 Marrie	и родіалітах родіалітах			+ Mest			a mut	10 Month	ing Minutes		94	- 12		-		
WP T CPD				Cther	Documents		1 1	2.00		1			92/22/2910	Administrator		45
WF S Comm	hing methodol		1.32		te MI report		S.m.	Annes	pd Deliverable				and a second second			-12
Case & Second		2		(D) Templ	ates.		1.10						02:22/2010	 Administrator 	· 3	46
		23					1	el Pariod	ic BMI reports					•**	• • • •	
ese 1000	2.4 4.53	69 - 3 5365	e 2009	1001201	0.0000	· · · · · ·	1.5			A	1.11.1	10010	.82(22(2010)	 Administrator. 	1001	47 .
		18. AN						-	Documents	5.		-		•		
		25			- 62		4 1	Dr Oaner	Locuments.	4	22	- 6	02/22/2010	Administrator	- 33	48
								-								
		8			81) 		5 10	E CMINA	TIN LINE	A	1.5	- 81	02/26/2010	 Christa Janko 	- 62	51
		. Ki												• 20		
202 202	NG 2003	672 10366		10000	S	100.00	5 17	5 Jempi	abes (25.5 - 27.5	200 C	12.55		03/26/2010	· Christe Janks-		78 .
		1024			141		-			10	~		19410102.00	2010/05/2011		1975
- 18 -		101			80		34		33		16	101		11	- 53	
-23		13 .			· June -		•		• **	37 *	- 22			1976	•23	
222		10.5	31	👗 New Fold	er 1 The	e file -	New r	ole () He	e O Delete	Config	100	325		50	265	
- 53		12	3.	and and a second a	A COLORA									•	- 33	
				Real?												



User Registration, Login and Dashboard






- ✓ User registration and login process
- ✓ Account management
- ✓ Personalised search
- Administer newsletter / feeds
- ✓ User administration and reporting

EMTRAIN pan-European extension







Login

Contact



Search



European Medicines Research and Training Network

Home

About EMTRAIN IMI E&T Programmes Partners Work Packages News Meeting Calendar

EMTRAIN will establish a sustainable, pan-European platform for education and training (E&T) covering the whole life-cycle of medicines research, from basic science through clinical development to pharmacovigilance. This will be achieved by integrating the strengths and competencies of the ESFRI BMS Infrastructures, the EFPIA companies, the current and future IMI E&T programmes as well as other scientific projects.

EMTRAIN is funded by the Innovative Medicines Initiative (IMI).



EMTRAIN travels Poland

Sitemap

EMTRAIN discusses expansion to Poland. The connection of partner universities to the European Clinical Research Infrastructures Network (ECRIN) in Warsaw will also have implications for EMTRAIN.

Read more

EMTRAIN participates in 5th ORPHEUS Conference

EMTRAIN will be represented by 2 key-note speakers at the 5th ORPHEUS Conference (Organisation for PhD Education in Biomedicine and Health Sciences in the European System), organized by the Medical University of



Communication materials



MISSION STATEMENT


EMTRAIN will establish a sustainable, pan-European platform for education and training covering the whole lifecycle of medicines research, from basic science through clinical development to pharmaco-vigliance.

E&T - THE FOUNDATION



This will be achieved by integrating the strengths and competencies of the ESFRI BMS Infrastructures, the EFPIA companies, the current and future IMI E&T Projects las members of the EMTRAIN Strategic Coordination Board), the current and future IMI Scientific Topics (as members of the EMTRAIN Network Committee) and external stateholders (as members of the EMTRAIN External Advisory Board).

STRUCTURE AND INPUTS



The EMTRAIN project, one oft the four ourrent IMI JU funded Education & Training Programmes, is coordinated by AstraZeneca. The Managing Entity is run by the Medical University of Vienna.

EMTRAIN's KEY OBJECTIVES

Complementary to the content producing IMI JU Education & Training Programmes (www.safesciemet.eu, www. pharmatrain.eu, www.eu2p.eu) EMTAIN aims at achieving more general objectives:

- Collection, evaluation and dissemination of information on Master Programmes, PhD Programmes and Continuing Professional Development Programmes in medicines research in the form of a pan-European online course catalogue
- Initial and continuing gap analyses regarding missing programmes, missing topics, lacking mobility of students and teachers, lacking geographic needs, new education methodologies and others
- Development of a toolkit of teaching concepts and methodologies (e-learning, distant learning, etc.)
- Development of new strategies and concepts for joint PhD programmes carried out in partnership between academia and industry
- Establishment of an online Students Office to provide advice and guidance to students as well as to allow for a broad exchange among students
- Promoting the expansion of IMI JU education & training initiative to new countries
- Assuring continuing information of all stakeholders: universities, researchers, industry, regulators, relevant governmental and non-governmental bodies, professional associations, patient organizations, general public.

PAN-EUROPEAN EXPANSION

EMTRAIN will implement creative strategies for pan-European expansion to all 27 EU Member States as well as associated countries. EMTRAIN will follow extension plans of the ESFRI BMS networks to broaden the IMI network which will be aimed at throughout the entire duration of the EMTRAIN project.

EMTRAIN PARTNERS & COUNTRIES



CCRIN - European Clinical Research Infrastructures Network (www.schin.org) ELIXIR - European Life Sciences Infrastructure for Biological Information (www.blinit.europe.org) EBMRI - Biobanking and Biomolecular Resources Research Infrastructure (www.bhint.eur) NETRUCT - Integrated Structural Biology Infrastructure for Europe (www.hnitwitucf.pT.eu) (MRAPRONTER - European Infrastructure for Phenotyping and Archiving of Model Mammatian Genomes (www.hnitwiters.eur) EATRIS - European Advanced Translational Research Infrastructure in Modifiche (www.antris.eu)



Summary of project



- Official Start date: 1st October 2009 (approved in February 2010)
- First Annual Report: Due on 30th November 2010
- Duration:
 - 7 years
- Overall Project Budget: EURO ~ 7.7 million
- First Pre-payment: March 2010 (EURO 600,000)



28 Project Partners



Public Partners: Members of the ESFRI BMS Infrastructures EATRIS, ECRIN, ELIXIR, BBMRI, INFRAFRONTIER & INSTRUCT

- Medizinische Universitaet Wien
- Karolinska Institutet
- Karolinska University Hospital
- University of Manchester
- Institut National de la Sante et de la Recherche Medicale
- European Molecular Biology Laboratory's European Bioinformatics Institute
- Helmholtz Zentrum für Infektionsforschung
- Medical University Graz
- Centre de Recherche en Biologie et Medecine
- Helmholtz München Gesundheit Umwelt
- University of Oxford
- Medical Research Council Hungary

EFPIA Partners:

- Astra Zeneca
- Genzyme Europe BV
- Novartis Pharma AG
- Bayer Schering Pharma AG
- Pfizer Ltd.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline R&D Ltd.
- UCB Pharma SA Belgium
- Novo Nordisk A/S
- Sanofi-Aventis R&D
- Boehringer-Ingelheim International GmbH
- JANSSEN Pharmaceutica NV
- ORION Pharma
- Almirall
- H. Lundbeck A/S
- Esteve





www.imi.europa.eu







Education & Training

European Medicines Research Training Network (EMTRAIN – www.emtrain.eu)

Coordinator: Astra Zeneca Managing Entity: Medizinische Universitaet Wien

Contacts: mike.hardman [AT] astrazeneca.com, +44 1625 519566 michael.wolzt [AT] meduniwien.ac.at, +43 1 40400 2980

